



EQUITY RISK SCIENCES, INC
Institutional Investment Data Analytics

THE BANKING CRISIS OF 2023

This report compares ERS's Risk Ratings on 11/1/2021 on 10 of the largest US banks with the recommendations of several of Wall Street's largest firms.

March 20, 2023

MEASURING THE RISKS OF INVESTING IN BANKS

- Over the past 16 months, the prices of 10 of the largest Regional Banks in America fell about 69%.
- Prior to declining, fourteen (14) of Wall Street’s largest brokerage firms gave them “buy” ratings.
- On average, these brokerages firms price targets, if achieved, would make their value \$253 billion.
- The current value of these banks is about \$85 billion, a difference of about \$168 billion.

EQUITY RISK SCIENCES, INC. uses data science to produce statistical analyses of the probability and magnitude of the price changes of individual securities.

- **On 11/15/2021, these banks’ average PRI™ rating was 92, very high risk.**
- **On 11/15/2021, each of these banks’ FRR™ rating was 100, the worst possible rating.**

Bank Name	Market Cap 11/15/2021	Market Cap 3/15/2023	Market Cap Loss 11/15/21 to 3/15/23	Price Loss 11/15/21 to 3/15/23	PRI™ 11/15/21	FRR™ 11/15/21
Comerica	\$11.8 billion	\$5.9 billion	\$5.9 billion	-47%	92	100
First Republic	\$39.4 billion	\$5.8 billion	\$33.6 billion	-86%	100	100
KeyCorp	\$22.3 billion	\$10.9 billion	\$11.3 billion	-48%	74	100
PacWest Bancorp	\$5.8 billion	\$1.4 billion	\$4.5 billion	-76%	90	100
Signature Bank	\$19.5 billion	\$4.4 billion	\$15.1 billion	-78%	100	100
Silvergate Bank	\$5.5 billion	\$0.07 billion	\$5.5 billion	-99%	100	100
SVB Financial	\$43.9 billion	\$6.3 billion	\$37.6 billion	-86%	88	100
Truist Financial	\$84.5 billion	\$42.6 billion	\$41.8 billion	-47%	77	100
Western Alliance	\$12.3 billion	\$3.5 billion	\$8.8 billion	-72%	100	100
Zions Bancorp	\$10.4 billion	\$4.6 billion	\$5.8 billion	-52%	95	100
Total	\$255 billion	\$86 billion	\$170 billion	-69%	92	100

Below is a list of the investment recommendations of 14 of the largest brokerage firms for investing in 10 of the largest regional banks in America.

Stock	Date	Price	Brokerage	Price Target	Analysts' Advice	Loss to 3/31/23
Comerica	1/20/22	\$93.54	RBC Capital	\$112	Outperform	-54%
Comerica	1/20/22	\$93.54	Wedbush	\$102	Outperform	-54%
Comerica	1/20/22	\$93.54	Raymond James	\$106	Outperform	-54%
First Republic	1/18/22	\$179.94	Evercore ISI Group	\$220	Outperform	-92%
First Republic	12/15/21	\$205.78	J.P. Morgan	\$250	Overweight	-93%
First Republic	4/14/22	\$160.75	Morgan Stanley	\$180	Equal-Weight	-91%
First Republic	4/8/22	\$158.13	UBS	\$194	Buy	-91%
KeyCorp	1/13/22	\$26.70	UBS	\$32	Buy	-53%
KeyCorp	12/15/21	\$23.11	B of A Securities	\$27	Buy	-46%
KeyCorp	4/11/22	\$20.86	Wells Fargo	\$27	Overweight	-40%
PacWest Banc	1/21/22	\$48.17	Raymond James	\$62	Strong Buy	-80%
PacWest Banc	6/15/22	\$27.37	Truist Securities	\$35	Buy	-64%
PacWest Banc	10/21/22	\$21.98	RBC Capital	\$31	Outperform	-56%
Signature Bank	1/19/22	\$351.43	Goldman Sachs	\$429	Buy	-100%
Signature Bank	1/19/22	\$351.43	Raymond James	\$440	Strong Buy	-100%
Signature Bank	6/6/22	\$223.35	UBS	\$309	Buy	-100%

Stock	Date	Price	Brokerage	Price Target	Analysts' Advice	Loss to 3/31/23
Silvergate Cap	3/21/22	\$139.96	B of A Securities	\$200	Buy	-99%
Silvergate Cap	1/20/22	\$109.34	Goldman Sachs	\$166	Buy	-99%
Silicon Valley Bk	1/21/22	\$581.76	Raymond James	\$780	Outperform	-100%
Silicon Valley Bk	7/23/21	\$570.87	RBC Capital	\$700	Outperform	-100%
Silicon Valley Bk	9/17/21	\$610.41	Wedbush	\$700	Outperform	-100%
Silicon Valley Bk	10/1/21	\$664.53	Goldman Sachs	\$770	Buy	-100%
Silicon Valley Bk	12/6/21	\$693.39	Morgan Stanley	\$985	Equal-Weight	-100%
Truist Financial	1/19/22	\$64.58	UBS	\$77	Buy	-47%
Truist Financial	4/7/21	\$59.43	Raymond James	\$65	Outperform	-43%
Truist Financial	9/12/22	\$49.54	Deutsche Bank	\$61	Buy	-31%
Western Alliance	4/25/22	\$80.20	Wedbush	\$105	Outperform	-56%
Western Alliance	6/15/22	\$72.86	Truist Securities	\$100	Buy	-51%
Zions Bancorp	2/14/22	\$72.36	Jefferies	\$87	Buy	-59%
Zions Bancorp	1/14/22	\$70.65	Compass Point	\$80	Buy	-58%
Zions Bancorp	1/6/22	\$68.94	Raymond James	\$76	Strong Buy	-57%

DISCLAIMER & FORWARD-LOOKING LANGUAGE

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Nothing contained in this presentation should be construed as legal, tax, financial, investment, or other advice.

In addition to historical information, this presentation contains statements relating to the future business performance, future catalysts and future events or developments, strategy, prospects, plans, objectives of management and future operations, and expected market growth of Equity Risk Sciences, Inc. (the “Company,”) that may constitute “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The words “believe,” “can make,” “intend,” “could,” “currently,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include but are not limited to the successful commercialization of our risk rating system and solutions, development of our sales and marketing capabilities, our ability to retain key management personnel including our Founder Ray Mullaney as well as Thomas Harpin, acceptance of our solutions by potential customers, the ability of our risk rating systems and solutions to provide valuable information related to a company’s stock price, and intellectual property litigation, and our ability to raise capital necessary for ongoing operations. The statements made herein speak only as of the date of this presentation. The Company’s actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. The Company undertakes no obligation to update or revise its forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.

Market data and industry information used herein are based on our management's knowledge of the industry and the good faith estimates of management. We also relied, to the extent available, upon managements review of independent industry surveys, forecasts and publications and other publicly available information prepared by a number of third-party sources. All of the market data and industry information used herein involves a number of assumptions and limitations which we believe to be reasonable, and you are cautioned not to give undue weight to such estimates. Although we believe that these sources are reliable, we cannot guarantee the accuracy or completeness of this information, and we have not independently verified this information. Projections, assumptions and estimates of our future performance and the future performance of the industry in which we operate are subject to a high degree of uncertainty and risk due to a variety of factors, including those described, above. These and other factors could cause results to differ materially from those expressed in our estimates and beliefs and in the estimates prepared by independent parties. In all cases, you should conduct your own investigation and analysis of the Company and the information contained in this presentation. All estimates and forecasts are subject to change and past results are not necessarily an indication of future performance.